Drug intelligence / Profile preview

bicalutamide + metformin

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

A combination of bicalutamide, an antiandrogen that blocks androgen receptors, and metformin, an antidiabetic medication with antineoplastic properties. This combination has been studied for its potential enhanced efficacy in treating prostate cancer. Preclinical studies showed the combination significantly reduces prostate cancer cell growth more than either monotherapy, with different mechanisms in AR-positive cells (reduced proliferation, G1/S cell cycle arrest) versus AR-negative cells (enhanced apoptosis).

Targets

AR (Adrenergic receptors)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on bicalutamide + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bicalutamide + metformin.

Explore the full profile